Xeris Pharmaceuticals XERS
$ 3.48
1.91%
Quarterly report 2024-Q3
added 11-08-2024
Xeris Pharmaceuticals Balance Sheet 2011-2024 | XERS
Annual Balance Sheet Xeris Pharmaceuticals
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
127 M | 66.7 M | 20.8 M | 49.4 M | 38.8 M | -13.8 M | -42 M | -32.3 M | - | - | - | - | - |
Long Term Debt |
191 M | 187 M | 88.1 M | 87 M | 58.3 M | 31.9 M | - | - | - | - | - | - | - |
Long Term Debt Current |
3.5 M | 1.58 M | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 97.2 M | 67.2 M | 34.4 M | 98 M | 62.9 M | - | - | - | - | - |
Total Current Liabilities |
95.2 M | 73.6 M | 79 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
329 M | 299 M | 209 M | 125 M | 94.6 M | 44.6 M | 103 M | 65.5 M | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | 232 K | 234 K | 263 K | - | - | - | - | - |
Retained Earnings |
-617 M | -555 M | -460 M | -337 M | -246 M | -121 M | -60.6 M | -34 M | - | - | - | - | - |
Total Assets |
323 M | 345 M | 304 M | 159 M | 109 M | 120 M | 45 M | 33.5 M | - | - | - | - | - |
Cash and Cash Equivalents |
67.4 M | 122 M | 67.3 M | - | - | - | - | - | - | - | - | - | - |
Book Value |
-6.78 M | 45.2 M | 95.2 M | 33.8 M | 14.4 M | 75.4 M | -57.8 M | -31.9 M | - | - | - | - | - |
Total Shareholders Equity |
-6.78 M | 45.2 M | 95.2 M | 33.8 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Xeris Pharmaceuticals
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
216 M | 230 M | 230 M | 191 M | 190 M | 188 M | 188 M | 187 M | 139 M | 138 M | 138 M | 88.1 M | 87.7 M | - | - | 87 M | 87 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
349 M | 351 M | 346 M | 329 M | 324 M | 315 M | 291 M | 299 M | 248 M | 245 M | 241 M | 209 M | 134 M | - | - | 125 M | 125 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-667 M | -651 M | -636 M | -617 M | -604 M | -591 M | -572 M | -555 M | -542 M | -520 M | -494 M | -460 M | -409 M | - | - | -337 M | -337 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
321 M | 332 M | 337 M | 323 M | 328 M | 329 M | 321 M | 345 M | 303 M | 319 M | 338 M | 304 M | 131 M | - | - | 159 M | 159 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
59.2 M | 57.6 M | 62.7 M | 67.4 M | 46.1 M | 46.2 M | 51 M | 122 M | 84.1 M | 95.3 M | 104 M | 67.3 M | 59.5 M | 63.6 M | 66.6 M | 37.6 M | 37.6 M | - | - | 19.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-28.3 M | -19.3 M | -9.18 M | -6.78 M | 3.86 M | 13.6 M | 30 M | 45.2 M | 55 M | 73.9 M | 96.5 M | 95.2 M | -2.46 M | - | - | 33.8 M | 33.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-28.3 M | -19.3 M | -9.18 M | -6.78 M | 3.86 M | 13.6 M | 30 M | 45.2 M | 55 M | 73.9 M | 96.5 M | 95.2 M | -2.46 M | 19.9 M | 44.4 M | 33.8 M | 33.8 M | 24.4 M | 27.1 M | 14.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency